 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【說說心理話】照顧者專欄作家：照顧者最需要的，是別人肯定他的付出，及認同他的情緒！分享照顧患認知障礙症長者心得► 即睇
